Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pless

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Schweizerische Medizinische Wochenschrift|January 11, 1994
[How long should cyclosporin be administered following bone marrow transplantation?]A Gratwohl, A Tichelli, G Stauffer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 1, 1995
Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center studyT Egger, A Gratwohl, A Tichelli, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 18, 2020
Choice of first line systemic treatment in pancreatic cancer among national expertsM Glatzer, D Horber, M Montemurro, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort studyS Schmid, D Klingbiel, S Aeppli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G D'Addario, D Rauch, R Stupp, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialC Gridelli, C Manegold, P Mali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2018
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological studyD Gramatzki, P Roth, E J Rushing, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)M Joerger, F Baty, M Früh, et al.
ESMO Open|April 15, 2022
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 studyM Mark, S Rusakiewicz, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Y Metaxas, M Früh, E I Eboulet, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Schweizerische Medizinische Wochenschrift|January 11, 1994
[How long should cyclosporin be administered following bone marrow transplantation?]A Gratwohl, A Tichelli, G Stauffer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 1, 1995
Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center studyT Egger, A Gratwohl, A Tichelli, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 18, 2020
Choice of first line systemic treatment in pancreatic cancer among national expertsM Glatzer, D Horber, M Montemurro, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort studyS Schmid, D Klingbiel, S Aeppli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G D'Addario, D Rauch, R Stupp, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialC Gridelli, C Manegold, P Mali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2018
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological studyD Gramatzki, P Roth, E J Rushing, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)M Joerger, F Baty, M Früh, et al.
ESMO Open|April 15, 2022
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 studyM Mark, S Rusakiewicz, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Y Metaxas, M Früh, E I Eboulet, et al.
Pageof 7